摘要
目的：探讨Ⅱ-Ⅲ期肺腺癌（lung adenocarcinoma）患者体内Bcl-2和Beclin-1基因、蛋白表达与新辅助化疗间关系。方法：经免疫组织化学法检测Ⅱ-Ⅲ期肺腺癌80例患者组织中Bcl-2和Beclin-1蛋白表达水平,利用实时定量聚合酶链反应法检测治疗后Ⅱ~Ⅲ期肺腺癌患者组织中Bcl-2和Beclin-1基因表达水平,并研究2种基因表达与新辅助化疗疗效间关系。结果：治疗前两组之间Bcl-2和Beclin-1的蛋白表达水平差异无统计学意义,且Beclin1与Bcl-2在肺腺癌中表达呈负相关,其相关性具有统计学意义（r=-0.43,P〈0.01）。实时定量聚合酶链反应法检测结果显示经新辅助化疗后,化疗组Beclin-1 m RNA水平明显高于对照组,而Bcl-2水平明显低于对照组,治疗前恰恰相反,差异有统计学意义（P〈0.05）。结论：利用新辅助顺铂和多西他赛方案术前化疗,可影响肺腺癌组织中Bcl-2和Beclin-1的表达水平,为研究抑制Bcl-2的表达提高临床参考。
Objective：To investigate the expressions of Bcl-2 gene and Beclin-1 gene and the efficacy of neoadju-vant chemotherapy in patients with stage Ⅱ-Ⅲ lung adenocarcinoma. Methods：Eighty patients with stageⅡ-Ⅲlung ade-nocarcinoma were randomly divided into two groups and were enrolled in the study before chemotherapy：one group accept-ed operation treatment after two weeks of neoadjuvant chemotherapy;the another directly accepted operation treatment.The expression of Bcl-2 and Beclin-1 were detected bv immunohistochemistry before chemotherapy and the correlation of the expression of Bcl-2 and Beclin-1 the response rate of chemotherapy was analyzed. The mRNA expression of Bcl-2 and Beclin-1 were measuerd by realtime-PCR after neoadjuvant chemotherapy. The relationship between the two groups and the change of the gene expression levels under the impact of neoadjuvant chemotherapy was studied. Result：There was no difference in Bcl-2 and Beclin-1 protein expression between the groups before chemotherapy,and was negatively correlated between Beclin 1 and Bcl-2 expression levels in lung adenocarcinoma （r=-0.43, P〈0.001）. It was showed that Bcl-2 and Beclin-1 mRNA levels were significantly different after neoadjuvant chemotherapy by realtime PCR.The results showed that the mRNA levels of Beclin-1 expression were significantly higher in chemotheroapy group than control group while the ex-pression of Bcl-2 decreased.The gene expression levels were the significant difference between the two groups （P〈0.05）. Conclusion： The data indicated that neoadjuvant chemotherapy might influence the expressions of Bcl-2 and Beclin-1 in lung adenocarcinoma and provide clinical reference for the inhibition of Bcl-2 expression.
出处
《交通医学》
2014年第5期449-452,455,共5页
Medical Journal of Communications
